Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | FADS1 | O60427 | 5/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472187 | 0.82 | GRM2 (0.36) | FADS1CETP | |
| SCHEMBL4463022 | 0.82 | MDM2 (0.39) | TNKSCYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL4449982 | 0.73 | HDAC1 (0.39) | — | |
| SCHEMBL4445382 | 0.69 | DHODH (0.46) | CETPKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4474713 | 0.67 | PDE3B (0.39) | — | |
| SCHEMBL4460627 | 0.67 | ALDH1A1 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL4472192 | 0.67 | GRM2 (0.35) | PTGDR2CETP | |
| SCHEMBL4445293 | 0.66 | ALDH1A1 (0.42) | KDM4EALDH1A1CYP3A4 | |
| SCHEMBL15744020 | 0.66 | KDM4E (0.49) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15744004 | 0.66 | KDM4E (0.49) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | TNKS 3250/4885PIK3CA 1781/4885PIK3CB 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.